HER2 Low Cancers Market: Epidemiology, Therapies, Companies, DelveInsight

HER2 Low Cancers Market, DelveInsight

HER2 Low Cancers treatments such as ENHERTU, DATROWAY (datopotamab deruxtecan), AIDIXI (disitamab vedotin), TRODELVY (sacituzumab govitecan), DB-1303, BNT323 (trastuzumab pamirtecan), Eftilagimod alpha (IMP321), Ifinatamab deruxtecan, BB-1701, ZIIHERA (zanidatamab), and others are anticipated to significantly drive the HER2 Low Cancers Market over the forecast period.

DelveInsight has introduced its latest publication, “HER2 Low Cancers - Market Insights, Epidemiology, and Market Forecast-2034,” offering a comprehensive evaluation of HER2 Low Cancers, including historical and projected epidemiology along with detailed market trends across the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Discover more about the HER2 Low Cancers market report  https://www.delveinsight.com/report-store/her2-low-cancers-market-forecast?utm_source=apac&utm_medium=pressrelease&utm_campaign=akpr 

Key Highlights from the HER2 Low Cancers Market Report:

As of 2024, the HER2-low cancer market in the United States was valued at nearly USD 1.6 billion, the highest among the 7 major markets (7MM), and is expected to witness robust growth through 2034.

In April 2025, Allogene’s dual-targeted allogeneic CAR-T therapy ALLO-329 (CD19/CD70) received FDA Fast Track Designation for refractory HER2 Low Cancers, including dermatomyositis, necrotizing myopathy, and anti-synthetase syndrome, along with lupus and scleroderma. The therapy is projected to initiate its Phase I RESOLUTION study by mid-2025, with proof-of-concept data anticipated by the end of the year.

In January 2025, RESTEM’s umbilical cord-derived stem cell therapy Restem-L obtained FDA Fast Track and Orphan Drug Designation for polymyositis and dermatomyositis. Early Phase I findings demonstrated 78% clinical improvement and a 35% reduction in steroid use. A Phase II/III trial (IIMPACT) is planned for Q1 2025.

Within the 7MM, breast cancer represents the largest share of HER2-low cases, followed by colorectal cancer, while ovarian cancer accounts for the smallest proportion. As the global population ages, breast cancer prevalence in older individuals continues to rise, and HER2-low tumors now constitute more than half of conventional breast cancer diagnoses.

Until 2022, HER2-low patients were generally treated similarly to HER2-negative patients, primarily with chemotherapy or endocrine therapy, particularly in HR-negative disease. A major milestone occurred in August 2022 when the FDA approved ENHERTU (trastuzumab deruxtecan) for HER2-low breast cancer based on the DESTINY-Breast04 trial. This landmark approval validated HER2-low as a distinct therapeutic target and paved the way for further advancements and earlier-line treatment strategies.

The HER2-low classification is also being explored across additional solid tumors, including gastric and urothelial cancers, thereby broadening its clinical significance. Key industry players in this dynamic space include AstraZeneca and Daiichi Sankyo (DATROWAY), Pfizer (disitamab vedotin), Gilead Sciences (TRODELVY), Duality Biologics and BioNTech (DB-1303/BNT323), Bliss Biopharmaceutical (BB-1701), and Merck and Daiichi Sankyo (ifinatamab deruxtecan).

Pipeline candidates targeting HER2-low cancers encompass TROP2-directed ADCs such as TRODELVY and DATROWAY, bispecific antibodies like zanidatamab, and immunotherapies including eftilagimod alpha, notable for its subcutaneous administration that enables at-home treatment and improved patient convenience.

Additionally, Dragonfly Therapeutics is advancing DF1001, a dual NK and T-cell engager designed for heavily pretreated HER2-low cancer patients, representing an innovative immunotherapy strategy.

In 2024, Japan reported approximately 15,000 cases of HER2-low urothelial carcinoma eligible for targeted therapy interventions.

Overall, the HER2-low cancer landscape is poised for substantial expansion, driven by an advancing pipeline, personalized treatment approaches, and the increasing global burden of cancer.

Leading companies such as Daiichi Sankyo and AstraZeneca, RemeGen and Pfizer (Seagen), Gilead Sciences, Duality Biologics and BioNTech, Immutep, Merck, Bliss Biopharmaceutical (Hangzhou), Zymeworks, Jazz Pharmaceuticals, ALX Oncology, Dragonfly Therapeutics, and others are actively developing innovative therapies to enhance the HER2 Low Cancers treatment ecosystem.

Prominent HER2 Low Cancers therapies include ENHERTU, DATROWAY (datopotamab deruxtecan), AIDIXI (disitamab vedotin), TRODELVY (sacituzumab govitecan), DB-1303, BNT323 (trastuzumab pamirtecan), Eftilagimod alpha (IMP321), Ifinatamab deruxtecan, BB-1701, ZIIHERA (zanidatamab), and others.

HER2 Low Cancers Overview

HER2 is a transmembrane tyrosine kinase receptor encoded by the ERBB2 gene and plays a central role in regulating cellular proliferation, differentiation, and survival. It belongs to the epidermal growth factor receptor (EGFR) family and is assessed through molecular diagnostic techniques such as immunohistochemistry (IHC) to measure protein expression and fluorescence in situ hybridization (FISH) to evaluate gene amplification. HER2-low tumors are characterized by an IHC score of 1+ or 2+ without gene amplification (FISH-negative or ISH-negative).

HER2/neu signaling occurs predominantly via the MAPK and PI3K pathways, contributing to oncogenesis when dysregulated. HER2 expression is observed across various malignancies, including breast, colorectal, ovarian, endometrial, bladder, gastric, and biliary tract cancers, with breast cancer being the most common.

The introduction of next-generation antibody-drug conjugates (ADCs) has significantly transformed the therapeutic paradigm for HER2-low tumors. ENHERTU, for instance, integrates a HER2-targeted monoclonal antibody with a potent topoisomerase I inhibitor, enabling precise delivery of cytotoxic therapy to HER2-expressing cancer cells.

HER2 Low Cancers Market Outlook

Therapeutic strategies for HER2-low cancers, including gastric, endometrial, and other solid tumors, are rapidly advancing as scientific insights into HER2 biology continue to evolve. Traditional options such as monoclonal antibodies and small-molecule tyrosine kinase inhibitors (TKIs) have demonstrated limited efficacy in tumors with low HER2 expression, creating opportunities for innovative targeted approaches.

Discover how the HER2 Low Cancers market is expanding in the coming years - https://www.delveinsight.com/report-store/her2-low-cancers-market-forecast?utm_source=apac&utm_medium=pressrelease&utm_campaign=akpr